Tricida in brief
Tricida is an unlisted company in the Biotechnology industry, based in South San Francisco, California, USA. It was founded in 2013. In the year to Dec 2021 it had sales of $0 M and a net loss of $176 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Tricida
Tricida is a Pharmaceutical company. It is focused on the development and commercialization of its investigational drug candidate, veverimer(is developed for the complications of chronic kidney disease (CKD) including metabolic acidosis), a non absorbed, orally administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease. The headquarters is in USA.
Tricida timeline
- 2013
- 🏁Founded
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔Initial public offeringFinal prospectus filed with the SEC on 29 June 2018; shares registered for exchange trading on 25 June 2018.
Events of Tricida from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Tricida
- Acquisitions and changes
- Delisted: it ended its SEC registration (Form 15) on 13 June 2023.
Market cap history
World rank over time
Rank in USA: #1,513 (Jan 2020) · #2,820 (Jan 2021) · #2,938 (Jan 2022) · #5,608 (Dec 2022)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -88000.0%
- Liabilities / assets
- 100.0%
- Net debt
- $-21M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2021 | — | — | $-153M | $-177M | — |
| Dec 2020 | — | — | $-251M | $-265M | — |
| Dec 2019 | — | — | $-179M | $-177M | — |
| Dec 2018 | — | — | $-104M | $-103M | — |
| Dec 2017 | — | — | $-47M | $-41M | — |
| Dec 2016 | — | — | $-27M | $-29M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2021 | $-140M | $0M | $-140M | $-3.44 | — |
| Dec 2020 | $-231M | $2M | $-233M | $-5.29 | — |
| Dec 2019 | $-130M | $1M | $-131M | $-3.72 | — |
| Dec 2018 | $-95M | $1M | $-96M | $-4.64 | — |
| Dec 2017 | $-40M | $1M | $-41M | $-19.32 | — |
| Dec 2016 | $-23M | $0M | $-23M | $-15.69 | — |
SEC filings
- Jun 13, 20238-KCurrent reportBankruptcy · Other events
- May 25, 20238-KCurrent reportBankruptcy · Regulation FD disclosure
- Apr 26, 20238-KCurrent reportRegulation FD disclosure
- Mar 24, 20238-KCurrent reportRegulation FD disclosure
- Mar 21, 20238-KCurrent reportDirectors or officers changed
- Mar 15, 20238-KCurrent reportAcquisition or disposal completed
- Feb 24, 20238-KCurrent reportMaterial agreement
- Feb 23, 20238-KCurrent reportRegulation FD disclosure
- Feb 17, 20238-KCurrent reportOther events
- Jan 27, 20238-KCurrent reportDirectors or officers changed
- Jan 17, 20238-KCurrent reportListing notice
- Jan 12, 20238-KCurrent reportMaterial agreement · Bankruptcy · Directors or officers changed · Bylaws amended
Official filings of Tricida with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- —
- Net income
- $-176 M
Dec-2021 ending year
Balance sheet
- Total assets
- $168 M
- Total liabilities
- $168 M
- Total equity
- $0 M
Dec-2021 ending year
Insider trading at Tricida#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Orbimed Advisors LLCDirector, 10% owner | Sellindirect | -3.63 M | $0.220 | — | 0 | Form 4 |
| filed | David P. BonitaDirector, 10% owner | Sellindirect | -3.63 M | $0.220 | — | 0 | Form 4 |
| filed | Robert J. AlpernDirector | Sell | -131,879 | $0.210 | — | 0 | Form 4 |
| filed | David P. BonitaDirector, 10% owner | Sellindirect | -5.62 M | $0.210 | — | 3.63 M | Form 4 |
| filed | Orbimed Advisors LLCDirector, 10% owner | Sellindirect | -5.62 M | $0.210 | — | 3.63 M | Form 4 |
| filed | Orbimed Advisors LLCDirector, 10% owner | Sellindirect | -1.03 M | $0.220 | — | 9.25 M | Form 4 |
| filed | David P. BonitaDirector, 10% owner | Sellindirect | -1.03 M | $0.220 | — | 9.25 M | Form 4 |
| filed | Robert J. AlpernDirector | Sell | -27,584 | $0.230 | — | 131,879 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Tricida#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Tricida scorecard#
Passes 3 of the 11 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 3). Fiscal year 2021.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-3.44 vs -5.29Diluted EPS -3.44 in fiscal 2021 against -5.29 the year before (report's currency).
- ✗Net income higher than five years earlier-$177 M-$177 M in fiscal 2021 against -$29 M in 2016.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$177 MNet income -$177 M in fiscal 2021.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2021.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-323.7%-323.7% in fiscal 2021.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities4.9×Current ratio 4.94 at the end of fiscal 2021.
- ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2021.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $21 M at the end of fiscal 2021.
- ✗Operating income covers interest five times-8.7×Operating income -8.7 times interest in fiscal 2021.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2021.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year2.5%Diluted shares up 2.5% in fiscal 2021.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Tricida: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 115−22.3%— | 148+11.6%— | 133+55.4%— | 86+138%— | 36+64.6%— | 22—— | |
| Selling, general and administrative | 38−63.5%— | 103+125%— | 46+154%— | 18+60.5%— | 11+109%— | 5.4—— | |
| Operating expenses | 153−39.2%— | 251+40.6%— | 179+72.6%— | 104+120%— | 47+73.4%— | 27—— | |
| Operating income | −153—— | −251—— | −179—— | −104—— | −47—— | −27—— | |
| Interest and finance income | 0.5−88.6%— | 4.4−49.4%— | 8.7+149%— | 3.5+775%— | 0.4+100%— | 0.2—— | |
| Interest expense and finance costs | 18−4.4%— | 18+220%— | 5.7+83.1%— | 3.1—— | 0—— | 0—— | |
| Other non-operating income (expense) | 0.1−97.7%— | 5.0−34.5%— | 7.7+95.3%— | 3.9+2044%— | 0.2+77.7%— | 0.1—— | |
| Income tax | 0—— | 0—— | −0.1—— | 0—— | 0—— | — | |
| Net income attributable to shareholders | −177—— | −265—— | −177—— | −103—— | −41—— | −29—— | |
| Earnings per share, basic | -3.44—— | -5.29—— | -3.72—— | -4.64—— | -19.32—— | -15.69—— | |
| Earnings per share, diluted | -3.44—— | -5.29—— | -3.72—— | -4.64—— | -19.32—— | -15.69—— | |
| Shares, weighted average (basic) | 51+2.5%— | 50—— | — | — | — | — | |
| Shares, weighted average (diluted) | 51+2.5%— | 50+5.3%— | 48+115%— | 22+936%— | 2.1+17.1%— | 1.8—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 21−84.7%12.5% | 138+642%39.2% | 19−50.0%5.0% | 37+280%15.0% | 9.8+72.0%13.8% | 5.7—— | |
| Short-term investments | 119−30.4%70.9% | 172−40.7%48.8% | 289+41.9%77.8% | 204+253%82.3% | 58—81.8% | — | |
| Other current assets | 5.0+11.5%3.0% | 4.5−5.4%1.3% | 4.7+45.1%1.3% | 3.3+71.2%1.3% | 1.9—2.7% | — | |
| Current assets | 146−53.7%86.4% | 314+0.4%89.3% | 313+28.0%84.1% | 244+252%98.6% | 69—98.4% | — | |
| Property, plant and equipment | 0.8−30.8%0.5% | 1.1−59.2%0.3% | 2.7+125%0.7% | 1.2+5.7%0.5% | 1.2—1.6% | — | |
| Right-of-use (leased) assets | 12−11.9%7.2% | 14+47.2%3.9% | 9.4—2.5% | — | — | — | |
| Total assets | 169−52.1%100% | 352−5.4%100% | 372+50.0%100% | 248+251%100% | 71—100% | — | |
| Accounts payable | 10+186%5.9% | 3.5−40.7%1.0% | 5.9−30.1%1.6% | 8.5+119%3.4% | 3.9—5.5% | — | |
| Debt due within a year | — | — | 0—0.0% | — | — | — | |
| Current liabilities | 29−13.9%17.5% | 34−13.8%9.7% | 40+169%10.7% | 15+31.9%6.0% | 11—15.9% | — | |
| Long-term debt | 0−100%0.0% | 77+31.3%21.8% | 58+53.3%15.7% | 38—15.4% | 0—0.0% | — | |
| Lease liabilities (non-current) | 11−13.4%6.7% | 13+48.5%3.7% | 8.8—2.4% | — | — | — | |
| Non-current liabilities | — | — | — | — | 0.3—0.5% | — | |
| Total liabilities | 168−30.7%99.9% | 243+125%69.0% | 108+102%29.0% | 53+362%21.5% | 12—16.4% | — | |
| Retained earnings | −810—−481% | −634—−180% | −369—−99.2% | −192—−77.5% | −89—−127% | — | |
| Shareholders' equity | 0.2−99.8%0.1% | 109−58.7%31.0% | 264+35.7%71.0% | 195—78.5% | −88—−125% | −48—— | |
| Total liabilities and equity | 169−52.1%100% | 352−5.4%100% | 372+50.0%100% | 248+251%100% | 71—100% | — | |
| Shares outstanding | 55+10.3%— | 50+0.9%— | 50+18.1%— | 42+1755%— | 2.3—— | — | |
| Cash-flow statement | |||||||
| Share-based compensation | 26−8.5%— | 28+12.4%— | 25+389%— | 5.2+488%— | 0.9+222%— | 0.3—— | |
| Cash from operating activities | −140—— | −231—— | −130—— | −95—— | −40—— | −23—— | |
| Capital expenditure | −0.1—— | −1.6—— | −1.4—— | −0.9—— | −1.0—— | −0.2—— | |
| Cash from investing activities | 64−54.2%— | 140—— | −127—— | −148—— | −38—— | −20—— | |
| Debt issued | — | — | — | 39—— | 0—— | 0—— | |
| Debt repaid | — | — | — | −0.1—— | −0.0—— | −0.0—— | |
| Shares issued | 75—— | — | — | — | — | — | |
| Cash from financing activities | −41−119%— | 210−11.9%— | 238−11.9%— | 271+228%— | 82+91.8%— | 43—— | |
| Change in cash | −117−198%— | 119—— | −19−168%— | 27+570%— | 4.1—— | −0.4—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 | Q1 FY2022to Mar 31, 2022 | Q4 FY2021to Dec 31, 2021 | Q3 FY2021to Sep 30, 2021 | Q2 FY2021to Jun 30, 2021 | Q1 FY2021to Mar 31, 2021 | Q4 FY2020to Dec 31, 2020 | Q3 FY2020to Sep 30, 2020 | Q2 FY2020to Jun 30, 2020 | Q1 FY2020to Mar 31, 2020 | Q4 FY2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 92−13.0%— | 20−25.2%— | 17−14.8%— | 19−42.5%— | 37*+34.8%— | 27−38.1%— | 20−31.2%— | 32−34.8%— | 27*−32.9%— | 43—— | 29—— | 49—— | 41*—— | |
| Selling, general and administrative | 32−35.9%— | 4.1−54.4%— | 9.8+2.9%— | 9.2−7.3%— | 9.1*−58.2%— | 9.1−69.1%— | 9.6−66.4%— | 9.9−57.9%— | 22*+24.6%— | 29—— | 28—— | 24—— | 17*—— | |
| Operating expenses | 124−20.4%— | 24−32.6%— | 27−9.0%— | 28−34.2%— | 46*−6.5%— | 36−50.6%— | 29−48.7%— | 42−42.3%— | 49−15.6%— | 72—— | 57—— | 73—— | 58—— | |
| Operating income | −124—— | −24—— | −27—— | −28—— | −46*—— | −36—— | −29—— | −42—— | −49*—— | −72—— | −57—— | −73—— | −58*—— | |
| Interest and finance income | — | — | — | — | — | — | — | — | 0.6*−70.0%— | 0.9—— | 1.2—— | 1.7—— | 2.0*—— | |
| Interest expense and finance costs | 10.0−49.8%— | 2.0−50.5%— | 2.0−49.7%— | 2.0−64.8%— | 4.1*−36.1%— | 4.0−36.3%— | 3.9+4.5%— | 5.6+178%— | 6.4*+310%— | 6.3—— | 3.8—— | 2.0—— | 1.6*—— | |
| Other non-operating income (expense) | 0.4−52.7%— | 0.3+4517%— | 0.1—— | 0.0−98.2%— | −0.0*−107%— | 0.0−99.3%— | −0.3−111%— | 0.4−45.3%— | 0.6*−55.9%— | 0.9—— | 2.7—— | 0.8—— | 1.4*—— | |
| Income tax | — | — | — | — | 0*−100%— | 0−100%— | 0—— | — | 0.1*—— | 0.0—— | −0.1—— | — | −0.1*—— | |
| Net income attributable to shareholders | −134—— | −26—— | −29—— | −30—— | −50*—— | −40—— | −34—— | −53—— | −55—— | −78—— | −58—— | −74—— | −58—— | |
| Earnings per share, basic | — | -0.44—— | -0.49—— | -0.51—— | — | -0.79—— | -0.67—— | -1.06—— | -1.09—— | -1.55—— | -1.16—— | -1.49—— | -1.17—— | |
| Earnings per share, diluted | — | -0.44—— | -0.49—— | -0.51—— | — | -0.79—— | -0.67—— | -1.06—— | -1.09—— | -1.55—— | -1.16—— | -1.49—— | -1.17—— | |
| Shares, weighted average (basic) | 58+15.0%— | 58+15.0%— | 58+15.0%— | 58+14.9%— | — | 50+0.6%— | 50+0.7%— | 50+0.8%— | — | 50—— | 50—— | 50—— | — | |
| Shares, weighted average (diluted) | 58+15.0%— | 58+15.0%— | 58+15.0%— | 58+14.9%— | — | 50+0.6%— | 50+0.7%— | 50+0.8%— | — | 50—— | 50—— | 50—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 18—18.9% | 18+4.5%18.9% | 22−3.1%19.4% | 18−56.3%12.6% | 21−84.7%12.5% | 17−42.8%10.3% | 23−45.4%11.7% | 41+284%17.2% | 138+642%39.2% | 30—7.4% | 42—9.2% | 11—3.3% | 19—5.0% | |
| Short-term investments | 62—66.5% | 62−51.9%66.5% | 77−49.9%67.0% | 106−40.2%75.5% | 119−30.4%70.9% | 130−55.0%78.9% | 153−55.8%78.4% | 177−35.3%75.4% | 172−40.7%48.8% | 288—72.1% | 346—75.6% | 274—85.5% | 289—77.8% | |
| Other current assets | 2.3—2.4% | 2.3−48.6%2.4% | 3.7−30.0%3.2% | 4.3+42.8%3.0% | 5.0+11.5%3.0% | 4.4−45.4%2.7% | 5.3−46.5%2.7% | 3.0−45.6%1.3% | 4.5−5.4%1.3% | 8.1—2.0% | 9.8—2.2% | 5.5—1.7% | 4.7—1.3% | |
| Current assets | 82—87.9% | 82−45.4%87.9% | 102−43.4%89.6% | 128−42.0%91.2% | 146−53.7%86.4% | 151−53.6%91.9% | 181−54.4%92.9% | 221−23.8%93.9% | 314+0.4%89.3% | 326—81.6% | 397—87.0% | 290—90.5% | 313—84.1% | |
| Property, plant and equipment | 0.5—0.6% | 0.5−35.3%0.6% | 0.6−34.6%0.5% | 0.7−34.7%0.5% | 0.8−30.8%0.5% | 0.8−53.1%0.5% | 0.9−34.8%0.5% | 1.1−25.8%0.4% | 1.1−59.2%0.3% | 1.8—0.4% | 1.4—0.3% | 1.4—0.4% | 2.7—0.7% | |
| Right-of-use (leased) assets | 11—11.6% | 11−13.7%11.6% | 11−13.0%9.9% | 12−12.4%8.4% | 12−11.9%7.2% | 13−11.5%7.6% | 13+48.7%6.7% | 13+47.9%5.7% | 14+47.2%3.9% | 14—3.6% | 8.7—1.9% | 9.1—2.8% | 9.4—2.5% | |
| Total assets | 94—100% | 94−43.0%100% | 114−41.4%100% | 140−40.3%100% | 169−52.1%100% | 165−58.8%100% | 195−57.3%100% | 235−26.6%100% | 352−5.4%100% | 400—100% | 457—100% | 320—100% | 372—100% | |
| Accounts payable | 4.4—4.7% | 4.4+34.8%4.7% | 3.7+36.6%3.3% | 5.5+4.0%3.9% | 10+186%5.9% | 3.3+82.5%2.0% | 2.7−53.1%1.4% | 5.3−51.6%2.3% | 3.5−40.7%1.0% | 1.8—0.4% | 5.8—1.3% | 11—3.4% | 5.9—1.6% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | 14—3.4% | 6.8—1.5% | — | 0—0.0% | |
| Current liabilities | 17—18.0% | 17−34.2%18.0% | 20−19.4%17.5% | 25−37.8%17.8% | 29−13.9%17.5% | 26−44.8%15.6% | 25−27.9%12.8% | 40−22.9%17.1% | 34−13.8%9.7% | 47—11.7% | 34—7.5% | 52—16.3% | 40—10.7% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 77+31.3%21.8% | 62—15.5% | 68—14.9% | 59—18.5% | 58—15.7% | |
| Lease liabilities (non-current) | 9.9—10.5% | 9.9−16.2%10.5% | 10−15.2%9.1% | 11−14.3%7.7% | 11−13.4%6.7% | 12−12.6%7.1% | 12+43.3%6.3% | 13+46.0%5.4% | 13+48.5%3.7% | 13—3.4% | 8.5—1.9% | 8.7—2.7% | 8.8—2.4% | |
| Total liabilities | 230—245% | 230+41.4%245% | 226+40.9%197% | 231+32.9%164% | 168−30.7%99.9% | 163−31.9%98.8% | 160−29.2%82.1% | 174+42.6%73.8% | 243+125%69.0% | 239—59.8% | 226—49.4% | 122—38.0% | 108—29.0% | |
| Retained earnings | −882—−939% | −882—−939% | −856—−749% | −828—−589% | −810—−481% | −760—−462% | −721—−370% | −687—−292% | −634—−180% | −579—−145% | −501—−110% | −443—−138% | −369—−99.2% | |
| Shareholders' equity | −136—−145% | −136−7256%−145% | −111−418%−97.3% | −90−247%−64.3% | 0.2−99.8%0.1% | 1.9−98.8%1.2% | 35−84.9%17.9% | 62−69.0%26.2% | 109−58.7%31.0% | 161—40.2% | 231—50.6% | 198—62.0% | 264—71.0% | |
| Total liabilities and equity | 94—100% | 94−43.0%100% | 114−41.4%100% | 140−40.3%100% | 169−52.1%100% | 165−58.8%100% | 195−57.3%100% | 235−26.6%100% | 352−5.4%100% | 400—100% | 457—100% | 320—100% | 372—100% | |
| Shares outstanding | 56—— | 56+10.4%— | 56+10.4%— | 55+10.2%— | 55+10.3%— | 50+0.5%— | 50+0.8%— | 50+0.7%— | 50+0.9%— | 50—— | 50—— | 50—— | 50—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 21−6.8%— | 0.8*−88.2%— | 7.1*+7.0%— | 6.5+8.0%— | 6.6*+106%— | 6.6−13.1%— | 6.6*−27.2%— | 6.0−27.8%— | 3.2*−66.1%— | 7.7—— | 9.1*—— | 8.4—— | 9.4*—— | |
| Cash from operating activities | −109—— | −19*—— | −26*—— | −26—— | −38*—— | −29*—— | −42*—— | −31—— | −42*—— | −60*—— | −78*—— | −51—— | −30*—— | |
| Capital expenditure | −0.0—— | −0.0*—— | 0*—— | 0—— | −0.0*—— | 0*—— | 0*—— | −0.1—— | −0.4*—— | −0.6*—— | −0.2*—— | −0.4—— | −0.3*—— | |
| Cash from investing activities | 67−68.7%— | 14*−37.9%— | 29*+21.5%— | 23+37.9%— | 0.2*−99.8%— | 23*−51.9%— | 24*—— | 17−60.4%— | 150*—— | 48*—— | −100*—— | 42—— | −3.2*—— | |
| Debt repaid | — | — | — | — | — | — | — | −0.0—— | — | −0.0*—— | −0.0*—— | −0.0—— | — | |
| Shares issued | — | — | 0*—— | 75—— | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 42—— | 0.1*+279%— | 0.6*+106%— | −0.2—— | 42*+43153%— | 0.0*−92.9%— | 0.3*−99.9%— | −83−15142%— | 0.1*−99.5%— | 0.2*—— | 209*—— | 0.6—— | 21*—— | |
| Change in cash | 0.8—— | −4.4*—— | 4.4*—— | −3.4—— | 4.1*−96.2%— | −5.9*—— | −18*−156%— | −97—— | 108*—— | −12*—— | 31*—— | −8.0—— | −12*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2022. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Tricida#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Bankruptcy or receivership 3 · Delisting notice 3 · Debt called early 2 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 7 · Agreement ended 1 · New debt 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Bankruptcy or receivershipShareholder rights changed | 8-K | |
| Bankruptcy or receivership | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completed | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Bankruptcy or receivershipDebt called earlyDirectors and officersMaterial agreementBylaws or fiscal year changed | 8-K | |
| Debt called early | 8-K | |
| Delisting noticeAgreement ended | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersResults announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jun 13, 2023
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | · | · | · | · | · | · | · | · | · | 93 | · | · | 93 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 93 people | Restructuring planSEC 8-K | “Under the restructuring plan, the Company is reducing its workforce by 93 employees (approximately 60%).” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Tricida compares in Biotechnology
- Revenue$0 M · higher than 0% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Tricida🇺🇸 | $9 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Dec 25, 2022 (last known)
- Annual results:
- Dec-2021 ending year
- Balance sheet:
- Dec-2021 ending year
- Profile updated:
- Nov 16, 2026
Figures from value.today research, Wikidata.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Tricida? Verify and update this profile — free
Show Tricida's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.